$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

$vbivq Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041082 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$853.0K	$6.624M	$317.0K
YoY Change	191.13%	1989.59%	196.26%
Cost Of Revenue	$2.943M	$2.530M	$2.672M
YoY Change	-11.57%	-5.31%	8.35%
Gross Profit	-$2.090M	$4.100M	-$2.355M
YoY Change	-31.14%	-274.1%	-0.17%
Gross Profit Margin	-245.02%	61.9%	-742.9%
Selling, General & Admin	$8.906M	$9.036M	$14.22M
YoY Change	-43.94%	-36.46%	46.7%
% of Gross Profit		220.39%
Research & Development	$1.368M	$1.532M	$4.983M
YoY Change	-45.67%	-69.26%	67.66%
% of Gross Profit		37.37%
Depreciation & Amortization	$470.0K	$500.0K	$526.0K
YoY Change	-9.62%	-4.94%	18.2%
% of Gross Profit		12.2%
Operating Expenses	$10.27M	$16.69M	$21.88M
YoY Change	-44.18%	-23.69%	72.72%
Operating Profit	-$12.36M	-$10.07M	-$21.56M
YoY Change	-42.33%	-53.29%	43.49%
Interest Expense	$13.35M	$1.543M	$958.0K
YoY Change	4380.2%	61.06%	-216.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$13.00K	-$20.44M	-$25.21M
YoY Change	-99.94%	-18.9%	59.08%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$156.0K	-$20.44M	-$25.21M
YoY Change	-99.26%	-18.9%	59.08%
Net Earnings / Revenue	-18.29%	-308.64%	-7952.37%
Basic Earnings Per Share		-$1.01	-$0.10
Diluted Earnings Per Share	-$0.01	-$1.01	-$97.61K
COMMON SHARES
Basic Shares Outstanding	23.69M shares	22.87M shares	258.3M shares
Diluted Shares Outstanding		21.17M shares	8.609M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.69M	$35.50M	$83.55M
YoY Change	-62.18%	-57.51%	-39.22%
Cash & Equivalents	$23.69M	$35.45M	$83.55M
Short-Term Investments
Other Short-Term Assets	$2.779M	$3.870M	$4.008M
YoY Change	-54.13%	-3.44%	-32.13%
Inventory	$8.499M	$7.540M	$5.796M
Prepaid Expenses	$2.284M	$2.930M	$2.730M
Receivables	$0.00	$353.0K	$132.0K
Other Receivables	$1.268M	$3.400M	$2.350M
Total Short-Term Assets	$36.23M	$50.15M	$96.22M
YoY Change	-53.36%	-47.88%	-34.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.91M	$9.423M	$11.15M
YoY Change	-2.77%	-15.48%	2.12%
Goodwill	$1.130M	$2.121M	$2.104M
YoY Change	-46.87%	0.81%
Intangibles	$36.50M	$35.60M	$57.73M
YoY Change	-37.44%	-38.33%
Long-Term Investments
YoY Change
Other Assets	$1.178M	$1.094M	$1.349M
YoY Change	-13.06%	-18.9%	23.31%
Total Long-Term Assets	$50.72M	$50.64M	$75.79M
YoY Change	-34.47%	-33.19%	-0.83%
TOTAL ASSETS
Total Short-Term Assets	$36.23M	$50.15M	$96.22M
Total Long-Term Assets	$50.72M	$50.64M	$75.79M
Total Assets	$86.95M	$100.8M	$172.0M
YoY Change	-43.93%	-41.41%	-23.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.431M	$7.008M	$11.67M
YoY Change	-50.43%	-39.93%	211.51%
Accrued Expenses	$6.602M	$7.900M	$13.50M
YoY Change	-55.45%	-41.48%	-2.81%
Deferred Revenue	$7.276M	$6.970M	$597.0K
YoY Change	1678.97%	1067.5%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$50.77M	$50.30M
YoY Change
Total Short-Term Liabilities	$75.74M	$77.19M	$34.68M
YoY Change	105.01%	122.58%	5.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00		$48.42M
YoY Change	-100.0%		73.3%
Other Long-Term Liabilities	$3.688M	$3.700M	$5.094M
YoY Change	-27.59%	-27.37%	59.39%
Total Long-Term Liabilities	$3.688M	$3.704M	$53.51M
YoY Change	-93.17%	-93.08%	71.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.74M	$77.19M	$34.68M
Total Long-Term Liabilities	$3.688M	$3.704M	$53.51M
Total Liabilities	$79.42M	$80.90M	$88.19M
YoY Change	-12.65%	-8.27%	37.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$582.4M	-$582.4M	-$468.5M
YoY Change	18.96%	24.33%
Common Stock	$561.6M	$559.9M	$442.3M
YoY Change	5.51%	26.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.527M	$19.89M	$83.82M
YoY Change
Total Liabilities & Shareholders Equity	$86.95M	$100.8M	$172.0M
YoY Change	-43.93%	-41.41%	-23.29%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$156.0K	-$20.44M	-$25.21M
YoY Change	-99.26%	-18.9%	59.08%
Depreciation, Depletion And Amortization	$470.0K	$500.0K	$526.0K
YoY Change	-9.62%	-4.94%	18.2%
Cash From Operating Activities	-$12.05M	-$7.960M	-$17.27M
YoY Change	-36.72%	-53.92%	328.64%
INVESTING ACTIVITIES
Capital Expenditures	$167.0K	$120.0K	-$1.300M
YoY Change	-88.5%	-109.23%	205.88%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$167.0K	-$120.0K	-$1.300M
YoY Change	-88.5%	-90.77%	205.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	268.0K	22.43M	19.44M
YoY Change		15.4%	175.51%
NET CHANGE
Cash From Operating Activities	-12.05M	-7.960M	-17.27M
Cash From Investing Activities	-167.0K	-120.0K	-1.300M
Cash From Financing Activities	268.0K	22.43M	19.44M
Net Change In Cash	-11.95M	14.35M	863.0K
YoY Change	-41.69%	1562.8%	-66.81%
FREE CASH FLOW
Cash From Operating Activities	-$12.05M	-$7.960M	-$17.27M
Capital Expenditures	$167.0K	$120.0K	-$1.300M
Free Cash Flow	-$12.22M	-$8.080M	-$15.97M
YoY Change	-40.38%	-49.42%	343.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0000764195
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants		usd
	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants		usd
CY2023Q3	VBIV	Warrants Issued In Connection With Financing Transactions Value WarrantsIssuedInConnectionWithFinancingTransactionsValue		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption		usd
	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions		usd
	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment		usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	VBIV	Contract With Customer Liability Deferred Revenue ContractWithCustomerLiabilityDeferredRevenue		usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2022	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37769
	dei	Entity Address Address Line1 EntityAddressAddressLine1	160 Second Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Floor 3
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02142
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	830-3031
	dei	Security12b Title Security12bTitle	Common Shares, no par value per share
	dei	Trading Symbol TradingSymbol	VBIV
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23687695	shares
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3704000	usd
CY2023Q3	us-gaap	Cash Cash	35454000	usd
CY2022Q4	us-gaap	Cash Cash	62629000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	353000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	94000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	7540000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2930000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2309000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3870000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	50147000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	77690000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1094000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1355000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9423000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12253000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2396000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3316000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35603000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58345000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	2121000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	50637000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	77396000	usd
CY2023Q3	us-gaap	Assets Assets	100784000	usd
CY2022Q4	us-gaap	Assets Assets	155086000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	7008000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12973000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11923000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6970000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	409000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	50299000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	994000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	972000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	77194000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36942000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1748000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2204000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1426000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2365000	usd
CY2023Q3	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	530000	usd
CY2022Q4	us-gaap	Accrued Participation Liabilities Due In Next Operating Cycle AccruedParticipationLiabilitiesDueInNextOperatingCycle	524000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	53981000	usd
CY2023Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23339220	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23339220	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8608539	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8608539	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	453901000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	442312000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	105955000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	90020000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	42462000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21440000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582432000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-489609000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19886000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100784000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	155086000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6624000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7829000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	789000	usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2525000	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2672000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9564000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	7948000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1532000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4983000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7975000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12988000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9036000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14220000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33237000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40234000	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3600000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	23600000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	16693000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	21875000	usd
	us-gaap	Operating Expenses OperatingExpenses	74376000	usd
	us-gaap	Operating Expenses OperatingExpenses	61170000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10069000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-21558000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66547000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-60381000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1543000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	958000	usd
	us-gaap	Interest Expense InterestExpense	4680000	usd
	us-gaap	Interest Expense InterestExpense	2799000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-8832000	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2693000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-21596000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-28982000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20444000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25209000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92823000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-92162000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20444000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25209000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92162000	usd
CY2023Q3	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants	862000	usd
	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants	862000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21306000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25209000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-93685000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-92162000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	7753000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-494000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	21022000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	23845000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12691000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25703000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71801000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68317000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.93
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.71
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.71
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21166818	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21166818	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608539	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8608539	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12840633	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12840633	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8608530	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8608530	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	64163000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2011000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-27751000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6599000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45022000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	45022000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1674000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-44628000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	6670000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8738000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	8738000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22339000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1500000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-20444000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	7753000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	19886000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	143882000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	681000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2502000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-21254000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5103000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	129564000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2457000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-45699000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	19236000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	105558000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	105558000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	105558000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1550000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	2412000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-25209000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-494000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	83817000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	83817000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92823000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-92162000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1516000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1541000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5185000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7371000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1411000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1237000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	23600000	usd
	VBIV	Inventory Reserve InventoryReserve	1547000	usd
	VBIV	Inventory Reserve InventoryReserve	1401000	usd
	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-975000	usd
	VBIV	Increase Decrease In Operating Right Of Use Assets IncreaseDecreaseInOperatingRightOfUseAssets	-1010000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-21891000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-28410000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	264000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	127000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3026000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5174000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	649000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	407000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2120000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	667000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-151000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	174000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5923000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7606000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6485000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	30000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-10051000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-3715000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-971000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1001000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48826000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-54649000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	697000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2892000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-697000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2892000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	23908000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1482000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	20000000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	563000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22426000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19449000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-78000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-52000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27175000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-38144000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	62629000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121694000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	35454000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83550000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4550000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2067000	usd
	VBIV	Non Cash Adjustments For Prior Periods From Adoption NonCashAdjustmentsForPriorPeriodsFromAdoption	681000	usd
	VBIV	Warrants Issued In Connection With Financing Transactions WarrantsIssuedInConnectionWithFinancingTransactions	10760000	usd
	VBIV	Warrants Modification In Connection With Debt Amendment WarrantsModificationInConnectionWithDebtAmendment	1550000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	67000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	283000	usd
	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	154000	usd
	VBIV	Share Issuance Costs Included In Accounts Payable And Other Current Liabilities ShareIssuanceCostsIncludedInAccountsPayableAndOtherCurrentLiabilities	67000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80C_eus-gaap--NatureOfOperations_z2UzEE84sz36" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_82B_z67N4K9L7op1">NATURE OF BUSINESS AND CONTINUATION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI Vaccines Inc. (the “Company” or “VBI”) was incorporated under the laws of British Columbia, Canada on <span id="xdx_906_edei--EntityIncorporationDateOfIncorporation_dd_c20230101__20230930_znXNk5AdLixl" title="Entity incorporation, date of incorporation">April 9, 1965</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its wholly owned subsidiaries, VBI Vaccines (Delaware) Inc., a Delaware corporation (“VBI DE”); VBI DE’s wholly owned subsidiary, Variation Biotechnologies (US), Inc., a Delaware corporation (“VBI US”); Variation Biotechnologies, Inc. a Canadian company and the wholly owned subsidiary of VBI US (“VBI Cda”); SciVac Ltd. an Israeli company (“SciVac”); SciVac Hong Kong Limited (“SciVac HK”); and VBI Vaccines B.V, a Netherlands company (“VBI BV”), are collectively referred to as the “Company”, “we”, “us”, “our”, or “VBI”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s registered office is located at Suite 1700, Park Place, 666 Burrard Street, Vancouver, BC V6C 2X8 with its principal office located at 160 Second Street, Floor 3, Cambridge, MA 02142. In addition, the Company has manufacturing facilities located in Rehovot, Israel and research facilities located in Ottawa, Ontario, Canada.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Reverse Stock Split</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company effected a </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20230411__20230412_zDpqExEt97Oa" title="Reverse stock split">1-for-30 reverse stock split</span> (the “Reverse Stock Split”) of its issued and outstanding common shares effective as of April 12, 2023, pursuant to which every 30 of the Company’s issued and outstanding common shares were automatically converted into one common share without any change in the par value per share. <span style="background-color: white">All share and per share amounts, including common shares underlying stock options, restricted stock units, and warrants, and applicable exercise prices, have been retroactively adjusted for all periods presented herein to give effect to the Reverse </span>Stock <span style="background-color: white">Split as required in accordance with United States of America generally accepted accounting principles (“U.S. GAAP”). Per the requirements of the <i>Business Corporations Act</i> (British Columbia), under which the Company is regulated, if fractional shares held by registered shareholders were to be converted into whole shares, each fractional share remaining after the completion of the Reverse </span>Stock <span style="background-color: white">Split that was less than half of a share was cancelled and each fractional share that was at least half of a share was rounded up to one whole share. No shareholders received cash in lieu of fractional shares.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal Operations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VBI is a commercial-stage biopharmaceutical company driven by immunology in the pursuit of prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B (“HBV”), COVID-19 and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2023 Organizational Changes</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As announced on April 4, 2023, the Company reduced its internal workforce by <span id="xdx_90B_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230403__20230404__srt--RangeAxis__srt--MinimumMember_zSId9Wqrogle" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_909_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230403__20230404__srt--RangeAxis__srt--MaximumMember_zVprHz21oJJc" title="Operating expenses and workforce reduction percentage">35</span>%, which began in April and was completed by the end of September 2023. As a result of this and other reductions in spend, VBI expects its operating expenses from normal business to be <span id="xdx_90E_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MinimumMember_zrYlWsQCIvMj" title="Operating expenses and workforce reduction percentage">30</span>-<span id="xdx_909_ecustom--OperatingExpensesAndWorkforceReductionPercentage_dp_uPure_c20230101__20230630__srt--RangeAxis__srt--MaximumMember_zCi7ADFAgaqh" title="Operating expenses and workforce reduction percentage">35</span>% lower in the second half of 2023 as compared with the second half of 2022<i>.</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>COVID-19 Endemic</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2023, the World Health Organization determined that COVID-19 no longer fit the definition of a public health emergency and the U.S. government announced its plan to let the declaration of a public health emergency associated with COVID-19 expire on May 11, 2023. COVID-19 is expected to remain a serious endemic threat for an indefinite future period and may continue to adversely affect the global economy, and we are unable to predict the full extent of potential delays or impacts on our business, our clinical studies, our research programs, the recoverability of our assets, and our manufacturing. The effects of the COVID-19 endemic, including but not limited to supply chain issues, global shortages of supplies, material and products, volatile market conditions and rising global inflation may continue to disrupt or delay our business operations, including with respect to efforts relating to potential business development transactions, and it could continue to disrupt the marketplace which could have an adverse effect on our operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company faces a number of risks, including but not limited to, uncertainties regarding the success of the development and commercialization of its products, demand and market acceptance of the Company’s products, and reliance on major customers. The Company anticipates that it will continue to incur significant operating costs and losses in connection with the development and commercialization of its products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an accumulated deficit of $<span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20230930_zK7yeyucyhC5">582,432</span> and cash of $<span id="xdx_900_eus-gaap--Cash_iI_pn3n3_c20230930_zbj3nzrybmvl">35,454</span> as of September 30, 2023. Cash outflows from operating activities were $<span id="xdx_90D_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20230101__20230930_zFGy33DUlJzf">48,826</span> for the nine months ended September 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company will require significant additional funds to conduct clinical and non-clinical trials, achieve and maintain regulatory approvals, and commercially launch and sell our approved products. Additional financing may be obtained from the issuance of equity securities, the issuance of additional debt, government or non-governmental organization grants or subsidies, and/or revenues from potential business development transactions, if any. There is no assurance the Company will manage to obtain these sources of financing, if required. If we are unable to obtain additional financing, we may be required to pursue a reorganization proceeding, including under applicable bankruptcy or insolvency laws. The above conditions raise substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2022, we 1) filed a registration statement on Form S-3 (File No. 333-267109), which included a base prospectus which covers the offering, issuance and sale of up to $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__srt--RangeAxis__srt--MaximumMember_z0hNHCJBjCa" title="Issuance and sale of common shares">300,000</span> of common shares, warrants, units and/or subscription rights; and 2) entered into an Open Market Sale Agreement with Jefferies LLC (“Jefferies”), pursuant to which we may offer and sell our common shares having an aggregate price of up to $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn3n3_c20220825__20220826__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember__srt--RangeAxis__srt--MaximumMember_zCr81Fq2JMja" title="Share value remaining, available for sale">125,000</span> from time to time through Jefferies, acting as agent or principal (the “ATM Program”). During the third quarter of 2023, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zaUK97ix08mf" title="Shares issued during period, shares">467,045</span> common shares under the ATM Program, for total gross proceeds of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zXY6wKV6ZBZb" title="Proceeds from issuance of equity">373</span> at a weighted average price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zRecbxKRCJM5" title="Average price per share">0.80</span> per share. The Company incurred $<span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zyiqAIbac5p1" title="Stock issuance costs">54</span> in sales agent commissions and share issuance costs related to the common shares issued in the quarter ended September 30, 2023, resulting in net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zsTSREoHn5ii" title="Net proceeds">319</span>. As of September 30, 2023, approximately $<span id="xdx_90C_ecustom--RemainingShareValueAvailableForIssuance_iI_pn3n3_c20230930__us-gaap--TypeOfArrangementAxis__custom--ATMProgramMember_zEruZmpW9LY" title="Share value remaining, available for sale">124,627</span> of common shares remained available for issuance under the ATM Program.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 5, 2023, the Company announced the expansion of its hepatitis B partnership with Brii Bio. Through (i) a Collaboration and License Agreement (the “Collaboration Agreement”), dated July 5, 2023, by and between the Company and Brii Bio, and (ii) the Amended and Restated Collaboration and License Agreement (the “A&R Collaboration Agreement, and together with the Collaboration Agreement, the “Brii Collaboration Agreements”), dated July 5, 2023, by and between the Company and Brii Bio, Brii Bio expanded its exclusive license to VBI-2601 to global rights and acquired an exclusive license for PreHevbri in Asia Pacific (“APAC”), excluding Japan. As part of this collaboration, Brii Bio paid the Company an upfront payment of $<span id="xdx_909_ecustom--UpfrontPayment_pn3n3_c20230704__20230705_zjD290FIfwhb" title="Upfront payment">15,000</span> consisting of a $</span><span id="xdx_904_eus-gaap--EquityMethodInvestmentAggregateCost_iI_pn3n3_c20230705__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zaPqPrbRDu2h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Equity investment">3,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">equity investment in a concurrent registered direct offering (discussed below), $</span><span id="xdx_90D_ecustom--PaymentClinicalAndCommercialManufacture_iI_pn3n3_c20230705_zxjlNO0Luim3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Payment for clinical and commercial manufacture">5,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as an advance payment for the clinical and commercial manufacture and supply of VBI-2601 and PreHevbri and any related manufacturing expenditures pursuant to a supply agreement (the “Supply Agreement”) dated July 5, 2023, by and between the Company and Brii Bio, and $</span><span id="xdx_905_ecustom--NonrefundableUpfrontPayment_iI_pn3n3_c20230705__dei--LegalEntityAxis__custom--BriiBiosciencesLimitedMember_zxTY074wJ769" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="Non-refundable upfront payment">7,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as a non-refundable upfront payment pursuant to the Brii Collaboration Agreements. In addition, pursuant to the Letter Agreement (the “Letter Agreement”), dated July 5, 2023, by and among the Company, SciVac, and Brii Bio, the Company also granted to Brii Bio a security interest, subject to a Subordination Agreement between Brii Bio and K2 HealthVentures LLC (“K2HV”), in all of its respective right, title, and interest in and to all intellectual property, know-how, and licenses to the extent related to PreHevbri and VBI-2601, and all proceeds of the foregoing, in order to secure performance of all of the Company’s obligations under the Brii Collaboration Agreements, the Supply Agreement, and the Loan Agreement (each as defined herein).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also eligible to receive up to an additional $<span id="xdx_907_ecustom--PotentialRegulatoryAndCommercialMilestonePayments_pn3n3_c20230704__20230705_zYBYHPzHYOh8" title="Potential regulatory and commercial milestone payments">422,000</span> in potential regulatory and commercial milestone payments (combined under the Brii Collaboration Agreements), and royalties in the licensed territories, which is worldwide for VBI-2601 and APAC, excluding Japan, for PreHevbri. Brii Bio will be responsible for all development, regulatory, and commercial activities and costs for the two programs in their respective licensed territories. There is no assurance that Brii Bio will achieve any of the milestones as specified in the Brii Collaboration Agreements and that we will receive any or all of these potential payments pursuant to the Brii Collaboration Agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2023, the Company closed (i) an underwritten public offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ1lQc31yrKf" title="Common shares, issued">12,445,454</span> common shares and accompanying common warrants to purchase up to <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z3pKBVNfSTde" title="Purchase of warrants">12,545,454</span> common shares (which included <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIcDXMN9w2Ji" title="Common shares, issued">1,536,363</span> common shares and common warrants to purchase up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsndd191aMc5" title="Purchase of warrants">1,636,363</span> common shares issued pursuant to the underwriters’ partial exercise of their option to purchase additional common shares and common warrants) at a combined public offering price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20230731_zqdqAe9eFNdl" title="Shares issued, price">1.65</span> per common share and accompanying common warrant, and (ii) a concurrent registered direct offering, pursuant to the expanded hepatitis B partnership with Brii Bio, of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zliNQDUAqJ84" title="Common shares, issued">1,818,182</span> common shares and accompanying common warrants to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_zvrcxvG1NIR8" title="Purchase of warrants">1,818,182</span> common shares, at a combined purchase price of $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20230731_zBDH7sxRodPi" title="Shares issued, price">1.65</span> per share and accompanying common warrant. The accompanying common warrants issued and sold in each of the underwritten public offering and the registered direct offering have an initial exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230731_zegfPbzmyytc" title="Warrant price">1.65</span> per share, which, pursuant to certain anti-dilution provisions of the warrants, was reduced to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930_zhoMxBVAib1k" title="Warrant price">0.6749</span> per share, as of September 30, 2023, and expire <span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dc_c20230701__20230731_zVSln96DjXs2" title="Expiration term">five years</span> from the date of issuance. The aggregate gross proceeds from the underwritten public offering, including aggregate gross proceeds from the underwriters’ exercise of their option to purchase additional securities, were $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zEN5LHVMytIh" title="Gross proceeds">20,500</span>. The aggregate gross proceeds from the concurrent registered direct offering were $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230701__20230731__us-gaap--SubsidiarySaleOfStockAxis__custom--DirectOfferingMember_z1aVKTa6jZkj" title="Gross proceeds">3,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the Company had outstanding warrants to purchase up to an aggregate of <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUpbHUNZI0N2" title="Warrants to purchase common stock">14,363,636</span> common shares, issued in July 2023. Pursuant to certain anti-dilution provisions of the warrants, as the consideration paid per common share under the ATM Program was less than the exercise price of such warrants in effect immediately prior to such issuance (“New Issuance Price”), the exercise price of the warrants (the “Exercise Price”) was reduced to the New Issuance Price. As of September 30, 2023, the Exercise Price in effect was $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230930_zyEWJlld3tGf" title="Warrant price">0.6749</span> per share, which resulted in a deemed dividend of $<span id="xdx_909_ecustom--DeemedDividendOnCertainWarrants_pn3n3_c20230101__20230930_zOcmacscWPP1" title="Deemed dividend">862</span> as the fair value of the warrants was greater subsequent to the reduction in Exercise Price than it was immediately prior to such reduction in Exercise Price. The fair values were determined using the Black-Scholes option pricing model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On November 1, 2023, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common shares for the 30 consecutive business day period between September 19, 2023 through October 31, 2023, it did not meet the minimum bid price of $1.00 per share required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until April 29, 2024 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In order to regain compliance with Nasdaq’s minimum bid price requirement, the common shares must maintain a minimum closing bid price of $1.00 for a minimum of ten consecutive business days during the Compliance Period. In the event that the Company does not regain compliance by the end of the Compliance Period, it may be eligible for additional time to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for the market value of our publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and will need to provide written notice of our intention to cure the deficiency during the second compliance period, by effecting a reverse stock split if necessary. If we meet these requirements, the Company may be granted an additional 180 calendar days to regain compliance. The Company has not regained compliance as of the date of this Form 10-Q, and if it fails to regain compliance during the Compliance Period or any subsequent grace period granted by Nasdaq, its common shares will be subject to delisting by Nasdaq, which could seriously decrease or eliminate the value of an investment in the common shares and result in significantly increased uncertainty as to the Company’s ability to raise additional capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments recognized in the condensed consolidated balance sheet consist of cash, accounts receivable, other current assets, accounts payable, and other current liabilities. The Company believes that the carrying value of its current financial instruments approximates their fair values due to the short-term nature of these instruments. The Company does not hold any derivative financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1965-04-09
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-30 reverse stock split
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-582432000	usd
CY2023Q3	us-gaap	Cash Cash	35454000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48826000	usd
CY2023Q3	VBIV	Upfront Payment UpfrontPayment	15000000	usd
CY2023Q3	VBIV	Payment Clinical And Commercial Manufacture PaymentClinicalAndCommercialManufacture	5000000	usd
CY2023Q3	VBIV	Potential Regulatory And Commercial Milestone Payments PotentialRegulatoryAndCommercialMilestonePayments	422000000	usd
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.65
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.65
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.65
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.6749
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P5Y
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.6749
	VBIV	Deemed Dividend On Certain Warrants DeemedDividendOnCertainWarrants	862000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1940000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2136000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1869000	usd
CY2023Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3464000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	3837000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	7540000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6599000	usd
CY2023Q3	us-gaap	Government Contract Receivable GovernmentContractReceivable	3470000	usd
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	4033000	usd
CY2023Q3	VBIV	Other Current Assets OtherCurrentAssets	400000	usd
CY2022Q4	VBIV	Other Current Assets OtherCurrentAssets	2026000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3870000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6059000	usd
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3600000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	23600000	usd
CY2023Q2	VBIV	Estimated Fair Value Of Assets Discount Rate EstimatedFairValueOfAssetsDiscountRate	0.15	pure
	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	142000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2023Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2023Q3	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-301000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	2121000	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	8714000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6292000	usd
CY2022Q4	VBIV	Goodwill Cumulative Currency Translation GoodwillCumulativeCurrencyTranslation	-295000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2127000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	6000	usd
CY2023Q3	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	3405000	usd
CY2022Q4	VBIV	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	6561000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1568000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3250000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1883000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4036000	usd
CY2023Q3	VBIV	Deferred Funding Current DeferredFundingCurrent	3925000	usd
CY2022Q4	VBIV	Deferred Funding Current DeferredFundingCurrent	6966000	usd
CY2023Q3	VBIV	Other Current Liabilities OtherCurrentLiabilities	1142000	usd
CY2022Q4	VBIV	Other Current Liabilities OtherCurrentLiabilities	1775000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11923000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22588000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16335798	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1094145	shares
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	50299000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	48888000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	50299000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	48888000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	55699000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	1588000	usd
CY2022Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	856000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	4586000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	2132000	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	470000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	416000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1411000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1237000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-172000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	515000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	486000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1317000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	742000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	1543000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	958000	usd
	us-gaap	Interest Expense InterestExpense	4680000	usd
	us-gaap	Interest Expense InterestExpense	2799000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1244	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9323	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0417	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0175	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.65
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	33.90
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1500000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2412000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5185000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7371000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6624000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7829000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	789000	usd
CY2023Q3	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8718000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2803000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2613000	usd
	VBIV	Contract With Customer Liability Deferred Revenue ContractWithCustomerLiabilityDeferredRevenue	8049000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1971000	usd
	VBIV	Contract With Customer Liability Currency Translation ContractWithCustomerLiabilityCurrencyTranslation	-27000	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8718000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6970000	usd
CY2023Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1748000	usd
CY2023Q3	VBIV	Deferred Funding Current DeferredFundingCurrent	3925000	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	399000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	489000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1373000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1383000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.13	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M3D
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	310000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1142000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	654000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	564000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	154000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2824000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	404000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2420000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	994000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1426000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6624000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	317000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7829000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	789000	usd

Files In Submission

Name	View Source	Status
0001493152-23-041082-index-headers.html	Edgar Link	pending
0001493152-23-041082-index.html	Edgar Link	pending
0001493152-23-041082.txt	Edgar Link	pending
0001493152-23-041082-xbrl.zip	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex10-7_001.jpg	Edgar Link	pending
ex10-8.htm	Edgar Link	pending
ex10-8_001.jpg	Edgar Link	pending
ex10-9.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vbiv-20230930.xsd	Edgar Link	pending
vbiv-20230930_cal.xml	Edgar Link	unprocessable
vbiv-20230930_def.xml	Edgar Link	unprocessable
vbiv-20230930_lab.xml	Edgar Link	unprocessable
vbiv-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq

2023 Q4 Form 10-Q Financial Statement

#000149315223041082 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ VBI Vaccines Inc/BC Stock $vbivq

2023 Q4 Form 10-Q Financial Statement

#000149315223041082 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VBIVQ
VBI Vaccines Inc/BC Stock $vbivq